SGLT2i and GLP-1RA in cardiometabolic and renal diseases: from glycemic control to adipose tissue inflammation and senescence

dc.centroUniversidad Cardenal Herrera-CEU
dc.contributor.authorD'Marco Gascón, Luis Gerardo
dc.contributor.authorMorillo, Valery
dc.contributor.authorGórriz, José Luis
dc.contributor.authorSuárez, María K.
dc.contributor.authorNava, Manuel
dc.contributor.authorOrtega, Ángel
dc.contributor.authorParra, Heliana
dc.contributor.authorVillasmil, Nelson
dc.contributor.authorRojas Quintero, Joselyn
dc.contributor.authorBermúdez, Valmore
dc.contributor.otherUCH. Departamento de Medicina y Cirugía
dc.contributor.otherProducción Científica UCH 2021
dc.date.accessioned2024-09-13T13:59:29Z
dc.date.available2024-09-13T13:59:29Z
dc.date.issued2021
dc.description.abstractBackground. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their documented benefits in cardiorenal and metabolic health. In this sense, and in addition to being used for glycemic control in diabetic patients, these drugs also have other favorable effects such as weight loss and lowering blood pressure, and more recently, they have been shown to have cardio and renoprotective effects with anti-inflammatory properties. Concerning the latter, the individual or associated use of these antihyperglycemic agents has been linked with a decrease in proinflammatory cytokines and with an improvement in the inflammatory profile in chronic endocrine-metabolic diseases. Hence, these drugs have been positioned as first-line therapy in the management of diabetes and its multiple comorbidities, such as obesity, which has been associated with persistent inflammatory states that induce dysfunction of the adipose tissue. Moreover, other frequent comorbidities in long-standing diabetic patients are chronic complications such as diabetic kidney disease, whose progression can be slowed by SGLT2i and/or GLP-1RA. The neuroendocrine and immunometabolism mechanisms underlying adipose tissue inflammation in individuals with diabetes and cardiometabolic and renal diseases are complex and not fully understood. Summary. This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise.es_ES
dc.identifier.citationD'Marco, L., Morillo, V., Gorriz, J.L., Suarez, M.K., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas-Quintero, J. & Bermúdez, V. (2021). SGLT2i and GLP-1RA in cardiometabolic and renal diseases: from glycemic control to adipose tissue inflammation and senescence. Journal of Diabetes Research, vol. 2021, i. 1 (jan.), art. 9032378. DOI: https://doi.org/10.1155/2021/9032378es_ES
dc.identifier.doihttps://doi.org/10.1155/2021/9032378
dc.identifier.issn2314-6745
dc.identifier.issn2314-6753 (Electrónico)
dc.identifier.urihttp://hdl.handle.net/10637/16160
dc.language.isoenes_ES
dc.publisherJohn Wiley & Sonses_ES
dc.relation.ispartofJournal of Diabetes Research, vol. 2021, i. 1 (jan.)
dc.rightsopen access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectEnfermedad cardiovasculares_ES
dc.subjectCardiovascular diseaseses_ES
dc.subjectAparato urinarioes_ES
dc.subjectUrinary systemes_ES
dc.subjectEnfermedades_ES
dc.subjectDiseaseses_ES
dc.subjectMetabolismoes_ES
dc.subjectMetabolismes_ES
dc.subjectGenética humanaes_ES
dc.subjectHuman geneticses_ES
dc.subjectTejido adiposoes_ES
dc.subjectAdipose tissuees_ES
dc.subjectDiabetes
dc.titleSGLT2i and GLP-1RA in cardiometabolic and renal diseases: from glycemic control to adipose tissue inflammation and senescencees_ES
dc.typeArtículoes_ES
dspace.entity.typePublicationes

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
SGLT2i_DMarco_JDR_2021.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format